Atlas Trials

TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases

Clinical trial NCT04512261 · WITHDRAWN

Trial details

NCT number
NCT04512261
Sponsor
Reva Basho
Status
WITHDRAWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Breast CancerBrain MetastasesHER2-positive Breast CancerCNS Disease
Start date
2022-06-01
Primary completion
2024-06-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.